1. Inhibition of ERK and JNK decreases both osmosensitive taurine release and cell proliferation in glioma cells.
- Author
-
Belsey MJ, Davies AR, Witchel HJ, and Kozlowski RZ
- Subjects
- 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid pharmacology, Animals, Anthracenes pharmacology, Apoptosis drug effects, Cell Cycle drug effects, Cell Line, Tumor, Dicumarol pharmacology, Imidazoles pharmacology, Ion Channels antagonists & inhibitors, Necrosis etiology, Niflumic Acid pharmacology, Nitrobenzoates pharmacology, Osmolar Concentration, Pyridines pharmacology, Rats, Astrocytoma metabolism, Cell Proliferation drug effects, Extracellular Signal-Regulated MAP Kinases antagonists & inhibitors, Flavonoids pharmacology, JNK Mitogen-Activated Protein Kinases antagonists & inhibitors, Taurine metabolism
- Abstract
Cell swelling is associated with the activation of an increase in the osmosensitive taurine release (OTR) rate, which serves to decrease cell volume as part of a process known as regulatory volume decrease. OTR, which is sensitive to many pharmacological agents including anion channel blockers and signalling pathway modulators, has also been suggested to play a role in cell cycle progression. At non-cytotoxic concentrations, the anion channel blocker NPPB (25 microM), the extra-cellular signal-regulated kinase inhibitor PD98059 (50 microM), and the c-Jun NH2-terminal kinase inhibitor SP 600125 (5 microM) each decreased the OTR rate by > or =50%, decreased cell proliferation, and increased G0/G1 cell cycle arrest.
- Published
- 2007
- Full Text
- View/download PDF